Acadia Pharmaceuticals Inc
ACAD
Market Cap$3.8B
Close$
$18.95
15.5% downside
Current Fair Value
15.5% downsideOvervalued by 15.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.80 Billion |
|---|---|
| Enterprise Value | $3.65 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $1.37 |
| Beta | 0.65 |
| Outstanding Shares | 166,808,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 16.55 |
|---|---|
| PEG | 112.66 |
| Price to Sales | 4.48 |
| Price to Book Ratio | 5.6 |
| Enterprise Value to Revenue | 3.66 |
| Enterprise Value to EBIT | 41.29 |
| Enterprise Value to Net Income | 15 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Acadia Pharmaceuticals Inc
CEO: Uli Hacksell